{"id":"NCT02249767","sponsor":"Spear Pharmaceuticals","briefTitle":"Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel","officialTitle":"Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2014-09-26","resultsPosted":"2020-01-13","lastUpdate":"2020-02-10"},"enrollment":574,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"Tretinoin","otherNames":["Placebo"]}],"arms":[{"label":"Generic Tretinoin","type":"ACTIVE_COMPARATOR"},{"label":"Brand Tretinoin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This was a double-blind, randomized, three-treatment, parallel study. Normal, healthy male and female children and adults (i.e., ages 12 to 40 years) with at least Grade 2 (i.e., mild severity) acne vulgaris were treated on the full face once daily for 84 days with the Tretinoin Gel 0.05%, Brand (tretinoin) Gel 0.05%, or Gel Vehicle. Acne lesions were graded by a single blinded observer at screening and at Weeks 0 (i.e., baseline), 2, 4, 8, and 12 at each location.","primaryOutcome":{"measure":"Percent Change in Baseline Acne Lesions at Week 12","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Generic Tretinoin","deltaMin":-32.34,"sd":30.35},{"arm":"Brand Tretinoin","deltaMin":-37.32,"sd":28.81},{"arm":"Placebo Vehicle","deltaMin":-26.38,"sd":32.33}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":230},"commonTop":["Irritation from Drug"]}}